Ascentage Pharma, IPO
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...
U.S. liquefied natural gas exporter Venture Global couldn’t have timed its initial public offering better: It comes just days ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...
The company intends to raise Rs 72.30 crore via initial share sale at the upper price band. The book built issue comprises of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback